The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation study of LY2523355, an Eg5 inhibitor, administered either on days 1, 5, and 9; days 1 and 8; or days 1 and 5 with pegfilgrastim (peg) every 21 days (NCT01214642).
K. C. Shih
No relevant relationships to disclose
J. R. Infante
No relevant relationships to disclose
K. P. Papadopoulos
Research Funding - Lilly
J. C. Bendell
No relevant relationships to disclose
A. W. Tolcher
Consultant or Advisory Role - Lilly
Research Funding - Lilly
H. A. Burris
No relevant relationships to disclose
M. Beeram
No relevant relationships to disclose
L. Jackson
No relevant relationships to disclose
R. Arcos
No relevant relationships to disclose
E. H. Westin
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
D. Farrington
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
A. McGlothlin
Employment or Leadership Position - Lilly
S. Hynes
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
J. Leohr
No relevant relationships to disclose
J. T. Brandt
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
A. Nasir
Employment or Leadership Position - Lilly
Consultant or Advisory Role - Lilly
A. Patnaik
Research Funding - Lilly